Investor Relations
Trading On:
CSE: VPH | OTCQB: VPHIF | FSE: VP2
Valeo Pharma (CSE:VPH) is a Canadian pharmaceutical company focused on four therapeutic areas: Respiratory, Neurology, Oncology and Specialty Products. Within these areas Valeo now has 8 marketed brands and 4 additional products contributing to significant growth for the coming year.
Investor Relation Contact
Frederic Dumais
Director Communications & Investor Relations
dumais@valeopharma.com
Head Office
16667, Hymus Boul.
Kirkland, Qc
H9H 4R9
Analysts
Chelsea Stellick
Industrial Alliance
1 (403)705-4982
Scott McAuley
Paradigm Capital
1 (416) 361-9080
Andre Uddin
Research Capital Corporation
1 (416) 860-8675
The Newsroom
VALEO PHARMA OBTAINS LISTINGS FOR REDESCA FROM TWO GPO REPRESENTING 700 HOSPITALS AND HEALTHCARE FACILITIES ACROSS CANADA
VALEO PHARMA OBTAINS LISTINGS FOR REDESCA FROM TWO GPO REPRESENTING 700 HOSPITALS AND HEALTHCARE FACILITIES ACROSS CANADA 2 Group Purchasing Organizations (GPO) listing agreements cover, Redesca™ and Redesca HP™, as well as 3 other Valeo hospital products The 2 multi-year product listings commenced on October 1, 2021 The GPOs together represent more than 700 hospitals […]
Valeo enters into LOI with PCPA for Enerzair and Atectura
VALEO PHARMA COMPLETES NEGOTIATIONS WITH PAN-CANADIAN PHARMACEUTICAL ALLIANCE FOR ENERZAIR® BREEZHALER® AND ATECTURA® BREEZHALER® Agreement to provide framework to participating jurisdictions in support of provincial public listings and reimbursements of both drugs Private payer health plan coverage exceeds 85% across Canada Scientific community demonstrates growing interest in both products MONTREAL, QUEBEC , October 5, 2021 […]
See all News →